Status:
COMPLETED
Validity of a French Version of the Severe Asthma Questionnaire
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Conditions:
Asthma
Eligibility:
All Genders
18-99 years
Brief Summary
"Severe asthma affects only 5% of asthmatics, but has a considerable impact on patients owing to the respiratory disability linked to asthma but also complications from oral corticosteroid (OCS) thera...
Detailed Description
"Difficult to treat asthma affects about 17% of the asthma population, among which 5% have severe asthma. For these patients, the disease is often a burden to their professional, family and personal ...
Eligibility Criteria
Inclusion
- Inclusion criteria :
- Adult patients
- Patients diagnosed with severe asthma as defined by the international consensus statement from European Respiratory Society and American Thoracic Society 2014: Asthma which requires treatment for GINA steps 4-5 asthma (high dose Inhaled Cortico Steroids \> 1000 micrograms and Long Action Beta Agonist or leukotriene or theophyllin modifier ) for the previous year
- \*or systemic CorticoSteroids for 50% of the previous year to prevent it from becoming ''uncontrolled'' or which remains ''uncontrolled'' despite this therapy
- Patient informed and not opposed to participating
- Exclusion criteria :
- Lung cancer, heart failure or Chronic Obstructive Pulmonary Disease, or other respiratory disease that may affect the evaluation of asthma
- Patient unable to read French
- Patient unwilling to take part in the research
- Patient under guardianship / curators
- Patient under AME
Exclusion
Key Trial Info
Start Date :
November 17 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 6 2023
Estimated Enrollment :
188 Patients enrolled
Trial Details
Trial ID
NCT04520633
Start Date
November 17 2020
End Date
July 6 2023
Last Update
December 15 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Bichat-Claude Bernard University Hospital
Paris, France, 75018